In December 2019, several cases of unknown pneumonia, later called coronavirus disease 2019 (COVID-19), were reported in Wuhan, China. Based on investigations, this highly infectious respiratory disease was caused by a novel RNA beta-coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (
1,
2). On March 24, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic due to its rapid global prevalence and dominance as a health problem causing high morbidity and mortality in a short period (
3). In Iran, the first confirmed patient with COVID-19 was reported in Qom province on February 19, 2020 (
4). Afterward, Iran turned into one of the pandemic epicenters (
5). Among patients with COVID-19, those having comorbidities, such as diabetes, high blood pressure, and cardiovascular diseases, had significantly poorer health outcomes (
6). More characteristically, the global quarantine during the COVID-19 pandemic negatively affected access to healthcare, including for patients with chronic diseases such as children with type 1 diabetes mellitus (T1DM) (
7-
9). The emergence of T1DM symptoms usually occurs quickly in children. Since diabetes ketoacidosis (DKA) is mainly caused by a delay in diagnosis and initiation of insulin therapy (
10), the early diagnosis of T1DM is crucial in preventing the disease progression towards DKA, which is an acute, life-threatening complication of diabetes (
11). The frequency and severity of DKA in children with T1DM are increasing in Germany, the USA, and UK, Italy, China, and Spain (
12-
18).